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Introduction
Dupuytren’s Disease is a benign, inherited, fibroproliferative
disease of the hand and fingers that leads to the formation of
nodules and cords, and can lead to significant contractures
of the palmar fascia. While discussed by Dupuytren in
the early 19th century, references to the condition have
likely been around for over 1500 years. An understanding
of the anatomy of the palmar fascia is critical to an
understanding of the disease, where normal fascia becomes
abnormal Treatment options have changed little since the
time of Dupuytren, though a deeper understanding of
the pathophysiology may lead to effective, non-surgical
treatments in the future. The history, epidemiology, clinical
presentation, pathophysiology, anatomy, and treatments of
Dupuytren’s Disease are reviewed herein.

History
The hand of benediction, or “manus apostolicus,” is a hand
with flexed ring and small fingers and extended long and
index fingers. The earliest known portrayal of this position
is in a mosaic at the Basilica of Sant’Apollinare Nuovo in
Ravenna, Italy dated to c500 A.D.1 A drawing by Albrecht
Dürer around 1508 A.D. called the “Study of the Hands of
an Apostle” depicts praying hands where the right small
finger is slightly flexed, unable to press flat against the left
hand. Perhaps an early Pope was afflicted by Dupuytren’s
disease. There are also Icelandic sagas, thought to originate
in the 12th and 13th centuries, telling of “miracle cures”
of contracted hands by priests in Iceland + Orkney.
Additionally, the “Curse of the MacCrimmons” is a Scottish
legend of a family of bagpipers in the 15th to 18th centuries
that was apparently “cursed” by the development of finger
contractures in their later years that prohibited them from
continuing to play the bagpipes.1-5
The first written description of anything resembling what
is now called Dupuytren’s Disease is credited to Felix Plater
in 1614 when he described a mason whose “tendons” of the
ring and little fingers “ceased to function.” In 1777, Henry
Cline (1750-1827) performed the first known dissection of
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an affected hand, thereafter proposing palmar fasciotomy
as a cure for the affliction. One of Cline’s students, Astley
Cooper (1768-1841), who himself became one of the great
surgical teachers in Europe, actually theorized in 1822,
years before Dupuytren, that chronic inflammation of
the palmar fascia could lead to contractures, and that the
aponeurosis “may with advantage be divided by a pointed
bistory.” Despite Cooper’s contributions, it was a lecture
by Guillaume Dupuytren (1777-1835) that later gave the
condition its eponym.
Dupuytren was an incredibly hard working individual
who truly went from poverty to nobility, being made a
Baron by King Louis XVIII. He held many positions at the
famous Hôtel-Dieu in Paris, France and made numerous
contributions to Medicine; at least 20 eponyms carry his
name.7 While respected for his work, he was not universally
liked; his contemporaries considered him “The greatest of
surgeons and the least of men” and “The Brigand (not Baron)
of Hôtel-Dieu.” Dupuytren hated to write; his teachings
were given in lectures and written down by his students. It
was a now famous lecture given in 1833 that really changed
the future. In his “Clinical Lectures on Surgery,” Dupuytren
attributed the contracture to the palmar aponeurosis and
stressed the normality of the joints involved. In addition
to describing the anatomy, he described the clinical
presentation, natural history, and surgical treatment of the
condition (fasciotomy), as well as the post-operative course.
Given this and his academic stature, the condition became
known as “Dupuytren’s Disease.” 7

Epidemiology
The distribution of Dupuytren’s Disease is often attributed
to the expansion of the Vikings. Upwards of 70% of people
of Northern European decent have Dupuytren’s Disease
though the penetrance is variable. The prevalence remains
the highest in Scandinavians and Scottish and it is very
rare in Hispanics, Black Africans, and Native Americans.3
There is a ~3-6% prevalence among whites world-wide. The
male:female ratio is about 9:1 and the prevalence increases

with age; the peak incidence in males is 40-59 years and the
peak in females is 50-69 years.
Many conditions (e.g. alcoholism, cigarette smoking,
diabetes mellitus (type II + type I), hyperlipidemia
(cholesterol and triglycerides), HIV, pulmonary TB, epilepsy,
RSD/CPRS/Sudeck’s Atrophy) have been associated with
Dupuytren’s Disease though a cause-and-effect relationship
remains undetermined.9 Since originally described by
Cooper and Dupuytren, manual work and injury have been
thought to be related to the development of Dupuytren’s
Disease, however recent studies have failed to show any
significant correlation with any particular occupation.
Because Dupuytren’s Disease is more common with age,
other conditions that also increase with age and have been
thought to be associated with Dupuytren’s Disease are likely
more coincidental than causative. There is however a clear
hereditary component as ~70% of patients have a family
history of Dupuytren’s Disease. While autosomal dominant
and autosomal recessive patterns have been considered, a
non-Mendelian inheritance, much like cardiovascular
disease, is most likely. As genetic predisposition appears
more important for the occurrence of Dupuytren’s Disease
than other medical or social comorbidities, it is rarely seen
at the University of New Mexico.
Clearly, certain individuals are more prone to developing
Dupuytren’s disease than others. In 1963, Hueston presented
criteria or “diathesis factors” for Dupuytren’s disease,
believing that the presence of these factors correlated
with the predisposition to develop Dupuytren’s Disease.
His criteria included: early onset (<40 years old); bilateral
involvement; positive family history; and the presence of
ectopic lesions (i.e not of the palmar fascia). If a patient
had none of these criteria, there was only a 17% chance of
disease recurrence or extension, while if all 4 criteria were
present, there was a 78% chance of recurrence or extension.4
These original criteria were later modified such that early
onset was considered <50 years old, ‘ectopic lesions’ were
restricted to only Garrod’s nodes (nodules on the dorsum
of the finger proximal interphalangeal joints), and male
gender was added. Many of these “diathesis factors” have
been linked to genetic markers (e.g SNPs) correlated with
Dupuytren’s Disease.10

Clinical Presentation
Patients typically present in their adult years with finger
joint contractures. The first manifestations of the disease
are actually skin changes such as skin pitting and nodule
formation though patients rarely present at this early
stage. Cord formation is also classic for Dupuytren’s
disease. Typically, cords are present most commonly in
line with the ring finger, followed by the small finger, long

finger, index finger, and thumb (in decreasing prevalence).
In diabetics, long finger and ring finger cords are more
common than small finger cords; females may also have a
more radial presentation and may have isolated web-space
or PIP involvement.8 As cords contracts, joint contractures
occur. Metacarpophalangeal (MCP) joint and proximal
interphalangeal (PIP) joint contractures are most common,
though distal interphalangeal joint contractures also
occur. The Hueston table top test is used to evaluate for
contractures; a positive test it one in which an individual
cannot place his/her hand flat on a flat surface (table
top) due to joint contractures. Patients may complain of
difficulties placing their hands in their pockets or shaking
hands because of the contractures. They may also note the
presence of lesions or contractures elsewhere, such as the
feet or genitals.6
The differential diagnosis of Dupuytren’s disease is
extensive; anything that can cause a digital contracture
should be considered. The differential includes, but is not
limited to: Trigger finger (stenosing tenosynovitis); Flexor
tendon adhesions; callus; camptodactyly; neoplasm (e.g
fibrosarcoma, epitheliod sarcoma, ganglion, soft-tissue
giant cell tumor); burn contracture; boutonniere deformity
(e.g from central slip injury or rheumatoid arthritis); posttraumatic deformity (e.g. fracture malunion, osteoarthritis,
stiffness); and ulnar or median neuropathy.5 There is also
an entity known as “Non-Dupuytren’s” contracture. NonDupuytren’s contracture is a non-progressive palmar fascial
proliferation associated with trauma, previous surgery, or
edema. Unlike in Dupuytren’s Disease, Non-Dupuytren’s
contractures affect an ethnically diverse population, are
typically unilateral without ectopic manifestations, and
may actually regress.11

Pathophysiology
While much has been learned about the pathophysiology
of Dupuytren’s Disease, much remains to be elucidated;
the exact pathogenesis remains elusive. The myofibroblast
has been shown to be the offending cell. This cell derives
from the normal fibroblasts of the palmar fascia under
influence of numerous cytokines (e.g. IL-1, TGF-β, et
al.); their activity is controlled both by mechanical forces
as well as autocrine/juxtracrine mechanisms. Known
contraction agonists include lysophosphatidic acid (LPA),
Prostaglandins (especially PGF2α), and TGF-β. γ-Interferon
has antagonistic affect in vitro. There is also an apparent
immunologic component as there are increased dermal
dendrocytes and inflammatory cells found in Dupuytren’s
cords, and there is an association with HLA-DR3. Molecular
analysis has also shown that there are increased androgen
receptors and increased collagen type III in Dupuytren’s
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fascia. Perhaps one of these findings will lead to a future
treatment and possible cure.

Anatomy
As Flatt wrote in 2001, “the development of Dupuytren’s
disease is always along anatomically identifiable connective
tissue structures.” 4 As such, knowledge of normal palmar
fascia is crucial to an understanding of Dupuytren’s
disease. The palmar fascia is composed of three main
aponeuroses: the radial aponeurosis, the ulnar aponeurosis,
and the central aponeurosis. A majority of the pathology
is seen in the central aponeurosis. This aponeurosis has
three main types of fibers: longitudinal; transverse; and
vertical. The longitudinal fibers are the pretendinous bands.
The transverse fibers include the natatory ligament (also
known as the superficial transverse metacarpal ligament)
which is contiguous with the distal commissural ligament
of the radial aponeurosis, and the transverse ligament of
the palmar aponeurosis (also known as Skoog’s ligament)
which is contiguous with the proximal commissural
ligament of the radial aponeurosis. The vertical fibers are
the vertical bands of Grapow and the septae of Legueu
and Juvara (SLJ). The SLJ divide the distal palm into seven
compartments (four for the flexor tendons and three for the
lumbricals and neurovascular bundles) and insert into soft
tissue confluences at the MCP joints.
The fingers also have elaborate fascial structures with
many, often variable, attachments. At the bases, there is a
web-space coalescence consisting of the spiral band, the
natatory ligament and the SLJ. The Gosset lateral digital
sheath (GLDS) has contributions from the natatory
ligament (superficial) and the spiral band (deep). There
is also intermittent fascial encasement of the digital
neurovascular bundles with Grayson’s ligament palmar,
Cleland’s ligament dorsal, GLDS lateral, and Thomine
retrovascular fascia medially.
Almost any of these normal fascial structures can become
pathologic in Dupuytren’s Disease. The vertical bands of
Grapow are involved in skin pitting and nodule formation.
The most common cords are: pretendinous cords; central
cords; spiral cords; natatory cords; Abductor digiti minimi
cords (“hypothenar cords”); lateral cords; retrovascular
cords; commissural “Y” cords; and radial thumb cords.
These cords can cause flexion contractions of the MCP
joints and interphalangeal joints; occasionally there will be
an extension contracture of the distal interphalangeal joint
due to involvement of the oblique retinacular ligament.
Also of note, Cleland’s ligament and Skoog’s ligament are
typically spared in Dupuytren’s Disease. The spiral cord,
lateral cord, digital cord, and hypothenar cord may displace
the neurovascular bundles.
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Treatments
In 1977, Hueston wrote of a treatment philosophy that still
holds true today: “Plan to do nothing for as long as possible,
and then do the minimum necessary to restore maximum
function.” 1 As such, non-operative treatment plays an
important role. Observation is the mainstay of nonoperative management. Radiation, ultrasound, Vitamin
E, and various medications have been tried though largely
abandoned due to their ineffectiveness. Occupational
therapy and splinting is still utilized. A variety of intralesional injections are also options. For early lesions, the
goal has been to modulate the myofibroblasts. While many
different injections have been tried (e.g calcium channel
blockers, azathiorinem prostaglandins, DMSO, et al.), only
γ-Interferon and corticosteroids injections have shown
beneficial effect. For advanced lesions, the goal has been
to dissolve the cord. Again, while many injections have
been tried (e.g. fibrinolysin, pepsin, trypsin, hyaluronidase,
et al.), Clostridial Collagenase (Xiaflex®) has risen to
the contemporary mainstream, primarily for isolated
pretendinous cords affecting only the MCP joint.
When non-operative treatment has failed, and the
contractures are considerably affecting a patient’s
function or quality of life, surgery in considered. There
are no universally agreed upon criteria for surgery, though
>30° flexion contracture at the MCP and >15° flexion
contracture at the PIP are frequently used indications. The
goal of surgical treatment is to control the disease, not to
cure it; a cure is likely only possible if the pathophysiology
is addressed. From a surgical standpoint, there is an
assortment of options spanning a range of aggressiveness.
On the least aggressive end of the spectrum is percutaneous
needle fasciotomy/aponeurotomy. Much like Dupuytren
himself detailed in the early 1830s, a variety of fasciotomy
techniques exist as well, including open and percutaneous,
single and segmental. The most common surgical technique
is a limited or regional fasciectomy. The most aggressive
surgical options include radical fasciectomy (McIndoe
procedure), dermatofasciectomy + skin grafting, fusions,
and amputations. With any procedure, additional variables
may be included such as the use of chemical adjuncts and/
or the addition of a PIP capsuloligamentous release. The
type of skin closure is also debated; primary closure with
or without local tissue rearrangement is most common,
though an open-palm technique and the use of free tissue
grafting also have their proponents. Despite numerous
studies, no technique has established itself as the most
effective, safest, or most reproducible.
No discussion of treatments is complete without
discussing complications. The primary complications of
non-operative treatment relate to the natural history of the

disease and the predisposition of the patient. With injections,
skin necrosis, fat necrosis, and flexor tendon ruptures are
possible. With surgery, rate and types of complications
vary substantially. Complications include: hematoma;
skin necrosis; skin tears; tendon rupture; digital nerve or
artery injury; infection; stiffness; and complex regional
pain syndrome (especially with concomitant carpal tunnel
release). And naturally, disease recurrence or extension is
common, ranging from a 20-80% risk for all interventions.
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Conclusion
Dupuytren’s Disease is a benign, inherited, fibroproliferative
disease of the palmar and digital fascias of the hand. In
Dupuytren’s disease, as normal becomes abnormal, a
deep understanding of anatomy is critical. Progression
and extension of the disease is related to individual
predisposition. There is a plethora of treatment options,
ranging in aggressiveness, though no treatment has
proven superior. Perhaps, in the future, with a greater
understanding of the disease pathophysiology, a nonoperative treatment will offer a cure. Currently, the goal of
treatment is not to cure but to restore as much function as
possible while avoiding complications.
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